SCHEMBL6177743

SCHEMBL6177743

Cc1ccc(Oc2cccc(Cl)c2C#N)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR8 Q9NR97 2/20 0.56
MAPT P10636 1/20 0.55
HSD11B1 P28845 1/20 0.54
AR P10275 4/20 0.46
ALDH1A1 P00352 1/20 0.44
BCL2L1 Q07817 1/20 0.44
MCL1 Q07820 1/20 0.44
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
SLC6A4 P31645 4/20 0.40
HTR2A P28223 3/20 0.40
MRGPRX4 Q96LA9 1/20 0.39
KCNH2 Q12809 2/20 0.39
LMNA P02545 1/20 0.39
ADRB2 P07550 1/20 0.38
CYP2D6 P10635 1/20 0.38
SLC6A2 P23975 1/20 0.38
CASR P41180 1/20 0.38
SLC6A3 Q01959 1/20 0.38
KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22169507 0.87 HSD11B1 (0.57) TLR8MAPTHSD11B1ARALDH1A1
SCHEMBL12780756 0.87 TLR8 (0.67) TLR8MAPTHSD11B1ARALDH1A1
SCHEMBL12122765 0.85 TLR8 (0.58) TLR8MAPTHSD11B1ARALDH1A1
SCHEMBL12568246 0.84 TLR8 (0.54) TLR8MAPTHSD11B1ARBCL2L1
SCHEMBL12731799 0.84 TLR8 (0.54) TLR8MAPTHSD11B1ARALDH1A1
SCHEMBL6177523 0.84 AR (0.52) TLR8MAPTHSD11B1ARALDH1A1
SCHEMBL12960258 0.83 TLR8 (0.53) TLR8MAPTHSD11B1ARALDH1A1
SCHEMBL12806825 0.83 HSD11B1 (0.57) TLR8MAPTHSD11B1ARBCL2L1
SCHEMBL11508991 0.82 TLR8 (0.52) TLR8MAPTHSD11B1ARALDH1A1
SCHEMBL12960259 0.82 TLR8 (0.54) TLR8MAPTHSD11B1ARBCL2L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960408-B2 Quinolinyl and benzothiazolyl modulators AMGEN INC. (US) 2011-06-14 US disclosed
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS AMGEN INC. (US) 2009-09-03 US disclosed
US-7166603-B2 Dihydropyrimidone inhibitors of calcium channel function BRISTOL-MYERS SQUIBB CO. (US) 2007-01-23 US disclosed
EP-1399137-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-12-14 EP disclosed
WO-2005009392-A2 DIHYDROPYRIMIDONE INHIBITORS OF CALCIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2005-02-03 WO disclosed
EP-1387679-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2004-08-11 EP disclosed
EP-1399137-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-03-24 EP disclosed
EP-1387679-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-11 EP disclosed
WO-2002089793-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed
WO-2002089785-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221635-A1 QUINOLINYL AND BENZOTHIAZOLYL MODULATORS PPARG, PPARA, PPARD TLR8 907/4885MAPT 3019/4885HSD11B1 1171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.